Clinical Trial Detail

NCT ID NCT03693612
Title GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

skin melanoma

transitional cell carcinoma

head and neck squamous cell carcinoma

prostate adenocarcinoma

clear cell renal cell carcinoma

lung non-small cell carcinoma

Therapies

GSK3359609 + Tremelimumab

Paclitaxel

Docetaxel

Cetuximab

Age Groups: senior adult

No variant requirements are available.